Current Oncology Reports

, Volume 8, Issue 4, pp 258–264

Second-line treatment of small-cell lung cancer

Article

Abstract

Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population. The only second-line treatment for small-cell lung cancer approved by the US Food and Drug Administration is topotecan. Other agents have been investigated and have shown modest efficacy. These include vinorelbine, irinotecan, etoposide, paclitaxel, and gemcitabine. Novel "targeted therapies" have shown disappointing results in this disease. Much of the recent work has focused on investigating alternative dosing and scheduling of topotecan. Combination therapies have also been investigated, and some have been shown to increase activity over single agents, but toxicity and quality of life variables are imperative in the treatment of this patient population.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Murray T, Ward E, et al.: Cancer statistics 2005. CA Cancer J Clin 2005, 55:10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Chrystal K, Cheong K, Harper P: Chemotherapy of small cell lung cancer: state of the art. Current Opin Oncol 2004, 16:136–140.CrossRefGoogle Scholar
  3. 3.
    Kassem J, Karnicka-Mlodkowska H, van PottelsbergheC, van GlabbekeM: Phase II study of vinorelbine in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993, 29A:1720.Google Scholar
  4. 4.
    Thatcher N, Eckardt J, Green M: Options for first and second line therapy in small cell lung cancer: a workshop discussion. Lung Cancer 2003, 41(Suppl 4):S37-S41.PubMedCrossRefGoogle Scholar
  5. 5.
    Lima C, Chiappori A: Treatment of relapsed small cell lung cancer: a focus on the evolving role of topotecan. Lung Cancer 2003, 40:229–236.CrossRefGoogle Scholar
  6. 6.
    Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090–2096.PubMedGoogle Scholar
  7. 7.
    Eckardt J, Gralla R, Palmer M, et al.: Topotecan as second line therapy in patients with small cell lung cancer: a phase II study. Ann Oncol 1996, 7(Suppl 5):107 (abstract 513).Google Scholar
  8. 8.
    Depierre A, von Pawel J, Hans K, et al.: Evaluation of topotecan in relapsed small cell lung cancer. A multicenter phase II study. Lung Cancer 1997, 18(Suppl 10):35 (abstract 126).Google Scholar
  9. 9.
    von PawelJ, Depierre A, Hans K, et al.: Topotecan in small cell lung cancer after failure of first line therapy: multicenter phase II study. Eur J Cancer 1997, 33(Suppl 8):S229.Google Scholar
  10. 10.
    von PawelJ, Schiller J, Shepherd F, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658–667. This phase III trial led to FDA approval of topotecan as second-line therapy for SCLC.Google Scholar
  11. 11.
    Eckhardt J, Depierre A, Ardizzoni A, et al.: Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer [abstract]. Proc ASCO 1997, 16:452a.Google Scholar
  12. 12.
    Armstrong D, Spriggs D, Levin J, et al.: Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005, 10:686–694.PubMedCrossRefGoogle Scholar
  13. 13.
    Koschel R, Huber R, Gatzemeirer U, et al.: Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy. Lung Cancer 2000, 29(Suppl 1):42.CrossRefGoogle Scholar
  14. 14.
    Treat J, Chao H, Lane S, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004, 9:173–181.PubMedCrossRefGoogle Scholar
  15. 15.
    Levin J, Lilenbaum G, Masters A, et al.: Association of topotecan with improved performance status in relapsed small cell lung cancer patients with poor performance status at baseline [abstract]. J Clin Oncol Proc ASCO 2004, 22(14S):7208. This reference gives justification for treatment of patients with poor performance status with relapsed SCLC.Google Scholar
  16. 16.
    Bence A, Mattingly C, Desimone P, et al.: Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells [abstract]. Proc Am Assoc Cancer Res 2002, 43:247.Google Scholar
  17. 17.
    Eckardt J: Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004, 9(Suppl 6):25–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Greco F, Burris H, Yardley D, et al.: Phase II trial of weekly topotecan in the second line treatment of small cell lung cancer. Lung Cancer 2003, 41(Suppl 2):237.CrossRefGoogle Scholar
  19. 19.
    von PawelJ, Ulrich G, Jen-Louis P, et al.: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive SCLC. J Clin Oncol 2001, 19:1743–1749. This reported study demonstrates similar efficacy of oral versus intravenous topotecan.Google Scholar
  20. 20.
    Eckardt J, von PawelJ, Hainsworth D, et al.: Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemo-sensitive small cell lung cancer (SCLC). An international phase III study [abstract]. Proc ASCO 2003, 22:619 (abstract 2488).Google Scholar
  21. 21.
    Ardizzoni A, Manegold C, Debruyne C, et al.: European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003, 9:143–150.PubMedGoogle Scholar
  22. 22.
    Stathopoulos G, Christodoulou C, Stathopoulos J, et al.: Second-line chemotherapy in small cell lung cancer n a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemother Pharmacol 2006, 57:796–800.PubMedCrossRefGoogle Scholar
  23. 23.
    Jordan C, Freiss G, Page R: Topotecan and vincristine as second line combination treatment of small cell lung cancer (SCLC) after failed first line therapy with carboplatin and etoposide [abstract]. Proc ASCO 2003, 22:686 (abstract 2757).Google Scholar
  24. 24.
    Le Chavalier T, Ibrahim N, Chomy P: A phase II study of irinotecan in patients with small cell lung cancer progressing after response to first-line chemotherapy [abstract]. Proc ASCO 1997, 16:450A.Google Scholar
  25. 25.
    De Vore R, Blanke C, Denham J, et al.: Phase II study of irinotecan in patients with previously treated small cell lung cancer [abstract]. Proc ASCO 1998, 17:451A.Google Scholar
  26. 26.
    Masuda N, Negoro S, Takifuji N, et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1998, 16:3329–3334.PubMedGoogle Scholar
  27. 27.
    Smit E, Fokkema E, Biesma B, et al.: A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer 1998, 77:347–351.PubMedGoogle Scholar
  28. 28.
    Kakolyris S, Mavroudis D, Tsavaris N, et al.: Paclitaxel in combination with carboplatin as salvage treatment in refractory small cell lung cancer: a multicenter phase II study. Ann Oncol 2001, 12:193–197.PubMedCrossRefGoogle Scholar
  29. 29.
    Dongiovanni V, Buffoni L, Berruti A, et al.: Second line chemotherapy with weekly paclitaxel and gemcitabine in patients with small cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2005, 6:1–7.Google Scholar
  30. 30.
    Masters G, Declerck L, Blanke C, et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003, 21:1550–1555.PubMedCrossRefGoogle Scholar
  31. 31.
    Krystal G, Hines S, Organ C: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56:370–376.PubMedGoogle Scholar
  32. 32.
    Wang W, Healy M, Sattler M, et al.: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000, 19:3521–3528.PubMedCrossRefGoogle Scholar
  33. 33.
    Rygaard K, Nakamura T, Spang-Thomsen M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993, 67:37–46.PubMedGoogle Scholar
  34. 34.
    Sekido Y, Obata Y, Ueda R, et al.: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991, 51:2416–2419.PubMedGoogle Scholar
  35. 35.
    Hibi K, Obata Y, Ueda R, et al.: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991, 6:2291–2296.PubMedGoogle Scholar
  36. 36.
    Johnson B, Fischer T, Fischer B, et al.: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9:5880–5887.PubMedGoogle Scholar
  37. 37.
    Dy G, Miller A, Mandrekar S, et al.: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16:1811–1816.PubMedCrossRefGoogle Scholar
  38. 38.
    Johl J, Chansky K, Lara P, et al.: The proteasome inhibitor PS-341(Bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial [abstract]. Proc ASCO 2005, 24:7047.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Hematology and OncologyUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations